Our data confirmed that increased CRM1 expression is an important risk factor for tumor clinical stage, tumor size, primary tumor invasion, lymph node metastasis, distant metastasis, and vascular and perineural involvement in laryngeal cancer patients. This evidence concerns the gene XPO1 and neoplasm.